TAK-573
TAK-573-1002
Phase 1 small_molecule terminated
Quick answer
TAK-573 for Relapsed and/or Refractory Multiple Myeloma is a Phase 1 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Relapsed and/or Refractory Multiple Myeloma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated